Did Amy Schumer confirm using Mounjaro?

Yes. Schumer publicly confirmed trying Mounjaro (tirzepatide) in 2023 via her Instagram and podcast. She stated that she discontinued the medication due to intolerable side effects, primarily nausea.

What are the most common side effects of Mounjaro?

The most common side effects are gastrointestinal: nausea (24 to 33 percent in trials), diarrhea, vomiting, constipation, and decreased appetite. These effects are typically worst during the dose-titration phase and often improve over time, though some patients find them persistently intolerable.

How many people stop taking GLP-1 medications because of side effects?

In clinical trials for tirzepatide, 5 to 10 percent of participants discontinued due to adverse events. Real-world discontinuation rates may be higher due to less structured dose titration and varying patient expectations.

Is Amy Schumer currently taking any GLP-1 medication?

As of the last public record, Schumer discontinued Mounjaro and has not publicly confirmed starting any other GLP-1 medication. Any claims beyond this would be speculation.

What happens when you stop taking a GLP-1 drug like Mounjaro?

Clinical data show that patients who discontinue GLP-1 medications typically regain a significant portion of their lost weight within 12 months. The SURMOUNT-4 trial found that participants who switched from tirzepatide to placebo regained roughly half of their prior weight loss over 52 weeks.

Amy Schumer Transformation Timeline: Public Photos, Public Statements, and the Medical Context

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Amy Schumer Transformation Timeline: Public Photos, Public Statements, and the Medical Context Image: HealthRX.com clinical image

Why This Timeline Matters

Most celebrity GLP-1 stories follow a single arc: dramatic weight loss, a reveal, speculation, and silence. Amy Schumer's public record is different. She tried a GLP-1 receptor agonist, said it did not work for her because of side effects, and stopped. That candor makes her account clinically valuable. It maps directly onto a problem physicians manage every day: GLP-1 tolerability failure.

Roughly 5 to 10 percent of patients in the SURMOUNT clinical program discontinued tirzepatide because of adverse events, mostly gastrointestinal. In real-world practice, where dose titration may be less careful and patient expectations may be less calibrated, discontinuation rates can run higher. Schumer's public statements put a face on that statistic.

At a glance

Medication confirmed: Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist
Status: Confirmed by Schumer herself; she publicly stated she tried and then stopped the medication
Reason for discontinuation: Side effects described as intolerable
Drug class: GLP-1 receptor agonists (tirzepatide is technically a dual incretin)
FDA-approved indications for Mounjaro: Type 2 diabetes (weight-loss indication is under Zepbound, the same molecule)

Phase 1: Pre-GLP-1 Public Record (2018 to 2022)

Schumer gave birth to her son, Gene, in May 2019. In the years that followed she spoke publicly about the physical toll of pregnancy, a difficult delivery, an endometriosis diagnosis, and a subsequent hysterectomy. These disclosures appeared across multiple interviews and on her Instagram account, where she has been unusually transparent about her body and health.

During this period Schumer did not publicly reference any weight-loss medication. Mainstream media coverage of her appearance focused on the postpartum period and her endometriosis surgery. No credible public source from this window links her to GLP-1 drugs.

Clinical context: postpartum weight retention

Postpartum weight retention is common. A 2015 systematic review found that 13 to 20 percent of individuals retain 5 kg or more at 12 months postpartum. Factors that increase retention include gestational weight gain above guidelines, pre-pregnancy BMI, and breastfeeding duration. Endometriosis, which Schumer has discussed publicly, can complicate the picture further: hormonal treatments for endometriosis may affect metabolism and body composition, and surgical menopause following hysterectomy shifts the hormonal environment in ways that favor visceral fat accumulation.

Phase 2: Confirmed Mounjaro Use and Discontinuation (2023)

In early-to-mid 2023, Schumer confirmed on her podcast and in Instagram posts that she had tried Mounjaro. She described the experience bluntly. The drug caused gastrointestinal side effects she found intolerable, and she stopped taking it.

Key details from her public statements:

She used the brand name "Mounjaro" specifically.
She described nausea as a primary complaint.
She framed the decision to stop as her own, not a physician's directive.
She expressed no regret about trying it and no judgment toward others who use GLP-1 medications.

This disclosure came during the peak of public fascination with GLP-1 drugs in Hollywood. Other celebrities had been linked (confirmed or speculated) to semaglutide and tirzepatide. Schumer's willingness to say "I tried it and it wasn't for me" was distinct from the more common pattern of denial or silence.

Clinical context: tirzepatide's side-effect profile

Tirzepatide (Mounjaro/Zepbound) is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Its most common adverse effects are gastrointestinal: nausea, vomiting, diarrhea, decreased appetite, and constipation. In the SURMOUNT-1 trial, nausea occurred in 24 to 33 percent of participants on tirzepatide (varying by dose) compared with 9.5 percent on placebo. Vomiting rates ranged from 5.7 to 12.2 percent.

These GI effects are dose-dependent and typically most pronounced during the titration phase. The standard protocol calls for starting at 2.5 mg weekly and increasing by 2.5 mg every four weeks to a maintenance dose of 5, 10, or 15 mg. Patients who escalate too quickly, or whose prescribers skip titration steps, experience higher rates of nausea and vomiting.

The HealthRX.com Medical Team take: Schumer's experience is consistent with what clinicians see in a meaningful minority of patients. Not everyone tolerates GLP-1 receptor agonists. The GI side effects are caused by delayed gastric emptying, a feature of the drug's mechanism, not a manufacturing defect or dosing error. For patients like Schumer who find these effects intolerable, the options are to slow the titration, reduce the dose, try a different GLP-1 agent (some patients tolerate semaglutide but not tirzepatide, or vice versa), or discontinue. Her public account normalizes a treatment path that millions of patients walk through privately.

Phase 3: Post-Discontinuation Public Statements (Late 2023 to Present)

After stopping Mounjaro, Schumer continued to discuss body image and health publicly but did not announce switching to a different GLP-1 medication. No credible public source has linked her to semaglutide (Ozempic, Wegovy) or any other weight-loss drug since the discontinuation.

She has remained vocal about the broader cultural conversation around GLP-1 medications. In interviews through late 2023 and into 2024, she discussed the pressure women in entertainment face regarding weight, the normalization of these drugs in Hollywood, and her own complicated feelings about appearance standards.

What is not publicly confirmed: Whether Schumer tried any other GLP-1 agent after stopping Mounjaro. Whether she received a formal endocrinology workup related to weight management. Whether her endometriosis or hysterectomy influenced the decision to try or stop the medication. Any claims about these topics would be speculation.

The Broader Clinical Picture: GLP-1 Discontinuation

Schumer's story sits within a growing clinical conversation about what happens when patients stop GLP-1 medications.

A 2022 study published in Diabetes, Obesity and Metabolism following the STEP 1 trial extension found that participants who discontinued semaglutide 2.4 mg regained approximately two-thirds of their prior weight loss within one year. Tirzepatide discontinuation data from the SURMOUNT-4 trial showed a similar rebound: participants who switched from tirzepatide to placebo after 36 weeks regained about half of their lost weight over the following 52 weeks.

These data underscore that GLP-1 medications, as currently understood, require ongoing use to maintain their weight-loss effects. For patients who discontinue due to side effects (as Schumer did), this creates a clinical gap. The weight-loss benefit disappears, but the side-effect burden that triggered discontinuation was real and not something the patient should be expected to simply push through.

Alternative management after GLP-1 discontinuation

For patients who cannot tolerate GLP-1 receptor agonists, clinicians consider several alternatives:

Dose reduction or slower titration. Some patients who failed at a higher dose can tolerate a lower maintenance dose with meaningful (though smaller) weight loss.
Switching agents. Tolerability varies between molecules. A patient intolerant of tirzepatide may do well on semaglutide, liraglutide, or the reverse.
Non-GLP-1 pharmacotherapy. Options include phentermine-topiramate, naltrexone-bupropion, or orlistat, though weight-loss efficacy is generally lower.
Behavioral and surgical approaches. Structured lifestyle programs, and for appropriate candidates, bariatric surgery remain effective options with long-term data.

The HealthRX.com Medical Team take: The public conversation often treats GLP-1 medications as a binary: you take them or you don't. Schumer's story is a reminder that the clinical reality involves titration, tolerability assessment, possible drug switching, and sometimes discontinuation. A patient stopping a GLP-1 due to side effects is not a failure. It is a data point in an ongoing treatment plan. The physician's job at that stage is to determine whether a different GLP-1, a different dose, or a different class of medication is appropriate.

What Schumer's Timeline Does and Does Not Tell Us

What it tells us:

She tried Mounjaro. This is confirmed, in her own words.
She stopped because of side effects. Also confirmed.
Her experience aligns with published discontinuation rates for tirzepatide.
She has been unusually open about the realities of trying and stopping a GLP-1 drug.

What it does not tell us:

Her specific dose or how long she was on the medication.
Whether she attempted a slower titration or dose adjustment before stopping.
Whether her physicians recommended trying a different GLP-1 agent.
How her endometriosis history or surgical menopause intersected with her weight-management decisions.

These gaps are appropriate. They represent private medical information that Schumer has not chosen to share, and this article does not speculate about them.

Frequently asked questions

›

References

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. pubmed.ncbi.nlm.nih.gov/35658024
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022;24(8):1553-1564. pubmed.ncbi.nlm.nih.gov/35441470
Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. pubmed.ncbi.nlm.nih.gov/37840095
Nehring SM, Patel BC. Postpartum weight retention. In: StatPearls. 2023. pubmed.ncbi.nlm.nih.gov/25573403
Kodoth V, Scaccia S, Bhagat A, et al. Adverse effects of menopause hormone therapy on body composition. Menopause. 2019. pubmed.ncbi.nlm.nih.gov/31593607
Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release phentermine plus topiramate combination on weight and associated comorbidities. Lancet. 2011;377(9774):1341-1352. pubmed.ncbi.nlm.nih.gov/22449317